Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Crossman

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|May 6, 2025
Professor Tipu Aziz (1956-2024)Alan Crossman, Timmy Aziz, John Stein
European Journal of Pharmacology|August 13, 2004
Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised ratsNaila Ismayilova, Alan Crossman, Alexei Verkhratsky, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 5, 2002
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseSusan H Fox, Brian Henry, Michael Hill, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 11, 2004
Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's diseaseSusan Fox, Montague Silverdale, Mark Kellett, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 24, 2004
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropiniroleMark J Millan, Benjamin Di Cara, Michael Hill, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 21, 2007
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivoMark J Millan, Per Svenningsson, Charles R Ashby, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Movement Disorders : Official Journal of the Movement Disorder Society|May 6, 2025
Professor Tipu Aziz (1956-2024)Alan Crossman, Timmy Aziz, John Stein
European Journal of Pharmacology|August 13, 2004
Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised ratsNaila Ismayilova, Alan Crossman, Alexei Verkhratsky, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 5, 2002
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseSusan H Fox, Brian Henry, Michael Hill, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 11, 2004
Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's diseaseSusan Fox, Montague Silverdale, Mark Kellett, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 24, 2004
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropiniroleMark J Millan, Benjamin Di Cara, Michael Hill, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 21, 2007
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivoMark J Millan, Per Svenningsson, Charles R Ashby, et al.
Pageof 1